Claims

1. Use of a pharmaceutical composition comprising a compound and at least one pharmaceutically acceptable excipient for the preparation of a medicament for sequestering one or more antibodies present in an individual; wherein the compound comprises

- a biopolymer scaffold and at least
- a first peptide n-mer of the general formula:

$$\mathbf{P\ (-S-P)_{(n-1)}}$$ and

- a second peptide n-mer of the general formula:

$$\mathbf{P\ (-S-P)_{(n-1)}}\ ;$$

wherein, independently for each occurrence, P is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids, and S is a non-peptide spacer,

wherein, independently for each of the peptide n-mers, n is an integer of at least 1, preferably of at least 2, more preferably of at least 3, especially of at least 4,

wherein each of the peptide n-mers is bound to the biopolymer scaffold, preferably via a linker each;

wherein the biopolymer scaffold is a protein selected from the group consisting of albumins and globulins and

wherein at least one occurrence of P is a circularized peptide;

wherein the composition is non-immunogenic in the individual and wherein the one or more antibodies present in the individual are specific for at least one occurrence of peptide P.

2. The use of claim 1, wherein at least 10% of all occurrences of P are circularized peptides, more preferably wherein at least 25% of all occurrences of P are circularized peptides, yet more preferably wherein at least 50% of all occurrences of P are circularized peptides, even more preferably wherein at least 75% of all occurrences of P are circularized peptides, yet even more preferably wherein at least 90% of all occurrences of P are circularized peptides or even wherein at least 95% of all

occurrences of P are circularized peptides, especially wherein all of the occurrences of P are circularized peptides.

3. The use of claim 1 or 2, wherein, independently for each occurrence, P is P_a or P_b,

wherein P_a is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids,

wherein P_b is a peptide with a sequence length of 2-13 amino acids, preferably 3-11 amino acids, more preferably 4-9 amino acids, especially 5-8 amino acids; and wherein

the first peptide n-mer is $\mathbf{P_a - S - P_a}$ and the second peptide n-mer is $\mathbf{P_a - S - P_a}$,

the first peptide n-mer is $\mathbf{P_a - S - P_a}$ and the second peptide n-mer is $\mathbf{P_b - S - P_b}$,

the first peptide n-mer is $\mathbf{P_b - S - P_b}$ and the second peptide n-mer is $\mathbf{P_b - S - P_b}$,

the first peptide n-mer is $\mathbf{P_a - S - P_b}$ and the second peptide n-mer is $\mathbf{P_a - S - P_b}$,

the first peptide n-mer is $\mathbf{P_a - S - P_b}$ and the second peptide n-mer is $\mathbf{P_a - S - P_a}$, or

the first peptide n-mer is $\mathbf{P_a - S - P_b}$ and the second peptide n-mer is $\mathbf{P_b - S - P_b}$.

4. The use of claim 3, wherein the peptide P_a and the peptide P_b are two different epitopes of the same antigen or two different epitope parts of the same epitope.

5. The use of any one of claims 1 to 4, wherein the biopolymer scaffold is selected from the group consisting of albumins, alpha1-globulins, alpha2-globulins and beta-globulins, in particular wherein the biopolymer scaffold is albumin, haptoglobin or transferrin.

6. The use of any one of claims 1 to 5, wherein the individual is a mammal, preferably a human, a non-human primate, a sheep, a pig, a dog or a rodent.

7. The use of claim 6, wherein the individual is a human.

8. The use of any one of claims 1 to 7, further for prevention or treatment of an autoimmune disease, wherein the individual has the autoimmune disease or is at risk of developing the autoimmune disease.

9. The use of any one of claims 1 to 7, further for prevention or treatment of transplant rejection in an individual having a transplant or eligible for a transplantation.

10. The use of any one of claims 1 to 7, further for prevention or treatment of adverse reactions based on anti-drug antibodies or anti-gene-delivery vector antibodies, in particular anti-AAV antibodies, wherein the individual undergoes therapy with the drug or is eligible for therapy with the drug, or wherein the individual undergoes gene therapy or is eligible for gene therapy,

preferably wherein the drug is a peptide or protein, especially selected from the group of enzymes, enzyme inhibitors, antibodies, antibody fragments, antibody mimetics, antibody-drug conjugates, hormones, growth factors, clotting factors and cytokines, preferably wherein the entire sequence, optionally with the exception of an N-terminal and/or C-terminal cysteine, of at least one occurrence of peptide P is identical to a sequence fragment of an amino-acid sequence of the peptide or protein, optionally wherein said sequence fragment comprises at most five, preferably at most four, more preferably at most three, even more preferably at most two, especially at most one amino acid substitutions.